Phase 4 N=28 Effect of Collagenase on Healing and Scarring
Scarring · Impaired Wound Healing
Primary: Time to Complete Wound Closure Collagenase Santyl and Vehicle — 12.9; 13.0 Days — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=61 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) — 14; 15; 6 Participants
Phase 4 N=30 Study of Medication Patch to Treat Children Ages 6-12 With ADHD
ADHD · Attention Deficit Hyperactivity Disorder
Primary: Efficacy Defined as Change From Baseline on the Investigator Rated DSM-IV Based ADHD Rating Scale, Over the Course of the Day. — 14.76; 28.33 Units on a scale — p=<.001
Phase 4 N=38 Treatments for Psychogenic Nonepileptic Seizures (NES)
Convulsion, Non-Epileptic · Conversion Disorder · Depression
Primary: Number of Nonepileptic Seizures (NES) — 5.0; 6.0; 3.0; 6.0 seizures — p=0.29
Phase 4 N=12 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
Stress Disorders, Post-Traumatic
Primary: Change in Clinician Administered PTSD Scale (CAPS) Scores — -3.40; -5.00 Units on a scale — p=0.7054
Phase 4 N=147 "Completeness of Response" Following Treatment With Treximet™ for Migraine
Migraine
Primary: Change in Scores From Completeness of Response Survey (CORS) — 0.17; 0.07; 0.03; 0.10 Units on a scale
Phase 4 N=115 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
Hepatitis C, Chronic
Primary: Percentage of Patients With Histologically-confirmed Recurrence of Hepatitis C Virus (HCV) — 61.8; 65.0 percentage of participants — p=0.725
Phase 4 N=451 Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4 — -29.6; -22.3 mm Hg
Phase 4 N=247 A Study of Different Use Regimens Using Two Acne Treatments
Acne Vulgaris
Primary: Change From Baseline in Total Facial Acne Lesion Count — 39.74; 40.02 Lesions
Phase 4 N=393 Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
Hypertension
Primary: Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement) — -13.65; -9.7 mmHg
Phase 4 N=443 Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -33.1; -27.8 mm Hg
Phase 4 N=83 Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Type 2 Diabetes Mellitus
Primary: Change in Time-averaged Glucose During a 24 Hour Period — -41.65; -29.56 mg/dL — p=<.001
Phase 4 N=78 Lab School Day Study for CONCERTA of Older Children With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Hour 4 Permanent Product Math Test Attempted Score (PERMP-Attempted) — 74.8; 103.5 Problems attempted — p=<0.0001
Phase 4 N=126 A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Cold Sore
Primary: Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore. — 39; 32 participants
Phase 4 N=228 A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Renal Transplantation
Primary: Renal Function Assessed by Calculated Glomerular Filtration Rate (cGFR) — 57.07; 51.73 mL/min/1.73m^2